Hristina Popovska* and Igor Petrov
Department of Neurology, University SS. Cyril and Methodius, Macedonia
*Corresponding Author: Hristina Popovska, Department of Neurology, University SS. Cyril and Methodius, Macedonia.
Received: July 29, 2020; Published: August 26, 2020
Over the past decade, it has been identified a novel disease entity in patients with Parkinson’s disease, impulse-compulsive spectrum disorder. Dopamine dysregulation syndrome (DDS) included in this group, is a syndrome characterized for a patients treated with dopaminergic therapy, especially Levodopa. The phenomenology of this syndrome is in a close relation with the current understanding of the basal ganglia function and its impact on a long-term management in patients with Parkinson’s disease.
Patients treated with dopaminergic therapy, develop cognitive and behavioral disturbances besides motor symptoms. The PD therapy which basically is dopamine replacement therapy (DRT) can relieve the motor symptoms. On the other hand, recent studies show that the same therapy can be a cause of behavioral alterations, especially when it is abused by the patients. It is very important to differentiate the psychological symptoms whether they are related to the disease itself or are а side effect from the therapy.
Keywords: Dopamine Dysregulation Syndrome; Parkinson’s Disease; Psychiatric Symptoms
Citation: Hristina Popovska and Igor Petrov. “Parkinson’s Disease Patients with Dopamine Dysregulation Syndrome-Editorial Review". Acta Scientific Medical Sciences 4.9 (2020): 90-96.
Copyright: © 2020 Hristina Popovska and Igor Petrov. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.